Voyager Therapeutics
VYGR
127 hedge funds and large institutions have $302M invested in Voyager Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 28 closing their positions.
63% more call options, than puts
Call options by funds: $633K | Put options by funds: $388K
4.62% more ownership
Funds ownership: 65.49% → 70.11% (+4.6%)
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
4% less funds holding
Funds holding: 132 → 127 (-5)
9% less capital invested
Capital invested by funds: $331M → $302M (-$29.5M)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.4M |
| 2 |
BlackRock
New York
|
+$7.67M |
| 3 |
AC
Armistice Capital
New York
|
+$4.43M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.47M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.96M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.45M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.44M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.62M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
151
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$16.2K | -1,743 | Closed |
|
|
QT
152
Quantbot Technologies
New York
| – | -$14K | -1,500 | Closed |
|
|
MIM
153
Macroview Investment Management
Bethesda,
Maryland
| – | -$7.99K | -858 | Closed |
|
154
Russell Investments Group
London,
United Kingdom
| – | -$400 | -43 | Closed |
|
|
AWM
155
Avior Wealth Management
Omaha,
Nebraska
| – | -$55 | -6 | Closed |
|
VYGR Hedge Fund Activity: Q2 2024 in Review
127 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2024, worth a combined $302M — down 8.9% from $331M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of VYGR and 23 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 43 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $13.4M. The largest seller was Acadian Asset Management, cutting an estimated $2.96M.
- 127 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2024, down from 132 in Q1 2024.
- Funds reported $302M of Voyager Therapeutics stock for Q2 2024, down 8.9% quarter-over-quarter.
- 23 funds opened new Voyager Therapeutics positions in Q2 2024 and 28 closed out, a net change of -5 holders.
- The largest Voyager Therapeutics buyer in Q2 2024 was Great Point Partners, an estimated $13.4M added.
- The largest Voyager Therapeutics seller in Q2 2024 was Acadian Asset Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q2 2024.